Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmonary hypertension.

Laurent P Nicod1

  • 1Pulmonary division, University Hospital, Geneva, Switzerland. laurent.nicod@hcuge.ch

Swiss Medical Weekly
|March 20, 2003
PubMed
Summary
This summary is machine-generated.

Pulmonary arterial hypertension (PAH) requires careful classification and differentiation from other conditions. Understanding PAH pathophysiology has led to new therapies targeting artery remodelling, with surgery as a last resort.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut-derived short-chain fatty acids modulate skin barrier integrity by promoting keratinocyte metabolism and differentiation.

Mucosal immunology·2022
Same author

Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID.

Respiration; international review of thoracic diseases·2021
Same author

A prevalent and culturable microbiota links ecological balance to clinical stability of the human lung after transplantation.

Nature communications·2021
Same author

Revue medicale suisse·2021
Same author

Chronic Obstructive Pulmonary Disease Rehabilitation and 6-Minutes Walk Test Revisited.

Respiration; international review of thoracic diseases·2020
Same author

Microbiome-induced antigen-presenting cell recruitment coordinates skin and lung allergic inflammation.

The Journal of allergy and clinical immunology·2020
Same journal

Metamizole-induced agranulocytosis: utilisation trends, pharmacovigilance signals and regulatory risk-minimisation in Switzerland.

Swiss medical weekly·2026
Same journal

Female genital mutilation/cutting and risk of obstetric anal sphincter injury at delivery.

Swiss medical weekly·2026
Same journal

Drug prescription before and after implementation of a CPOE system on the Paediatric Intensive Care Unit: a quality improvement study.

Swiss medical weekly·2026
Same journal

Trends in health- and lifestyle-related aspects in women of childbearing age: analysis of Swiss Health Survey data between 1992 and 2022.

Swiss medical weekly·2026
Same journal

Microplastics in the air and potential health risks - a narrative review.

Swiss medical weekly·2026
Same journal

Potentially inappropriate medication: prevalence, risk of hospitalisation and associated healthcare costs in the general older population of Switzerland.

Swiss medical weekly·2026
See all related articles

Area of Science:

  • Cardiology
  • Pulmonology
  • Pathology

Background:

  • Pulmonary arterial hypertension (PAH) is a complex condition requiring precise classification.
  • PAH must be distinguished from other forms of pulmonary hypertension, such as those caused by thromboembolic diseases.
  • Histologically, PAH involves characteristic pulmonary artery remodelling, including intimal thickening, medial proliferation, and plexogenic lesions.

Purpose of the Study:

  • To outline the classification and differentiation of pulmonary arterial hypertension.
  • To highlight the histological hallmarks of PAH.
  • To discuss the evolution of therapeutic strategies for PAH based on improved physiopathological understanding.

Main Methods:

  • Review of current understanding of PAH classification and pathophysiology.

Related Experiment Videos

  • Analysis of histological features of pulmonary arteries in PAH.
  • Evaluation of established and emerging therapeutic interventions for PAH.

    • Main Results:

    • PAH classification includes primary PAH and PAH secondary to conditions like collagen vascular diseases, HIV, or portal hypertension.
    • Effective differentiation from thromboembolic pulmonary hypertension is crucial for appropriate management.
    • New therapies targeting prostacyclins, endothelin receptors, and phosphodiesterase inhibitors aim to dilate arteries and prevent remodelling.

    Conclusions:

    • Accurate diagnosis and classification of PAH are essential for guiding treatment.
    • Advances in understanding PAH pathophysiology have enabled targeted medical therapies.
    • Surgical options like thromboendarterectomy, septostomy, and transplantation are reserved for cases refractory to medical treatment.